Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast long-term extension in pediatric Behçet's disease oral ulcers or juvenile psoriatic arthritis
2022-003024-41Phase 3Active
- Sponsor
- Amgen
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of apremilast in Behçet's disease (BD) and juvenile psoriatic arthritis (JPsA) (2 cohorts), sponsored by Amgen. Primary endpoint: Adverse events. Started Nov 2022; status: active.
02
Drugs
apremilast
03
Conditions
Behçet's disease (BD)juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on 2022-003024-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003024-41.